Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: Multicentric study of the GEC-ESTRO Breast Cancer Working Group

Hannoun-Lévi, J.-M.; Resch, Alexandra; Gal, Jocelyn; Kauer-Dorner, Daniela; Strnad, Vratislav; Niehoff, Peter; Loessl, K.; Kovács, G.; Limbergen, Erick Van; Polgár, Csaba

doi:10.1016/j.radonc.2013.03.026

Cited by 136 publications

(100 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Excellent local control with acceptable early toxicity was observed [72]. An additional re-irradiation series with brachytherapy has also reported favorable results [73]. Mature data are still needed to establish repeat lumpectomy with APBI as a valid alternative to mastectomy for some women ipsilateral breast tumor recurrence following breast conserving therapy.…”

Section: Reirradiationmentioning

confidence: 98%

Proton Therapy for Breast Cancer: Progress & Pitfalls

Corbin

Mutter

2018

Breast Cancer Manag.

View full text Add to dashboard Cite

Practice points• Proton therapy is under investigation for early stage and locally advanced breast cancer.• Due to unique physical properties, proton therapy reduces the dose to the heart, lungs, skin, muscle, and bone and is therefore hypothesized to reduce side effects from treatment.• Proton therapy may also enable improved target coverage in some breast cancer patients.• Due to its highly conformal nature, proton therapy requires careful attention to target volume delineation and implementation of strategies to mitigate uncertainties in setup and delivery.• Proton therapy for breast cancer is rapidly evolving with improvements in techniques for treatment delivery and optimizing of dose and fractionation schedules.• Research is ongoing to determine whether proton therapy improves treatment outcomes and quality of life compared with conventional photon techniques.As the number of patients cured from breast cancer increases with improvements in multidisciplinary care, emphasis on reducing late toxicities of treatment has increased, in order to improve long-term quality of life. Proton beam therapy (PBT) is a form of radiotherapy that uses particles with unique physical properties that enable treatment delivery with minimal dose deposition beyond the treatment target. Therefore, PBT has emerged as an exciting radiotherapy modality for breast cancer due to the ability to minimize exposure to the heart, lungs, muscle, and bone. Herein, we review the rationale for PBT in breast cancer, potential clinical applications, and the available clinical data supporting its use. We also address some of the technical and logistical challenges and areas of ongoing research that will ultimately establish the role for PBT for breast cancer in the years ahead.First draft submitted: 5 January 2018; Accepted for publication: 13 March 2018; Published online: 13 April 2018Keywords: breast cancer • cardiotoxicity • heart • particle therapy • pencil-beam scanning • proton therapy • radiation therapyBreast cancer accounts for 30% of new cancer diagnoses in women [1]. Although breast cancer remains the second leading cause of cancer death among women, advances in detection and treatment have resulted in improved outcomes, with 5-year expected survival of 90% [1]. Radiation therapy (RT) is indicated in the management of the majority of women with breast cancer [2]. For early stage breast cancer, breast irradiation following lumpectomy is an essential component of breast conserving therapy, lowering the risk of recurrence and improving breast cancer specific survival [3,4]. Recently published clinical trials also support the oncologic value of regional nodal irradiation (RNI) in some women with high risk node negative or axillary nodal metastases [5,6]. In addition, women with locally advanced breast cancer benefit from RT to the chest wall and regional lymph nodes, delivered in the post mastectomy setting [7]. While RT is widely utilized and improves breast cancer treatment outcomes, RT is also associated with late effects including cardi...

show abstract

Section: Reirradiationmentioning

confidence: 98%

Proton Therapy for Breast Cancer: Progress & Pitfalls

Corbin

Mutter

2018

Breast Cancer Manag.

View full text Add to dashboard Cite

show abstract

“…Az ismételt emlőmegtartó műtét utáni reirradiáció té-májában a legtöbb közlemény a szövetközi sugárkezelés módszerének alkalmazásával született [35][36][37][38][39][40][41][42][43][44]. Ezen vizsgálatok eredményeit az 5. táblázatban foglaltuk ösz-sze.…”

Section: Eredeti Közleményunclassified

“…EMM = második emlőmegtartó műtét; 2. LR = második lokális recidíva; MAST = mastectomia; NA = nincs adat; OS = teljes túlélés; † hároméves lokális recidíva és teljes túlélés; *tízéves teljes túlélés portja közölte 2013-ban [36]. A tanulmány 217 azonos oldali lokális kiújulás miatt 2000 és 2010 között második emlőmegtartó műtéttel és multikatéteres szövetközi sugárkezeléssel ellátott beteg adatait dolgozta fel nyolc európai intézet közreműködésével.…”

Section: Táblázatunclassified

Második emlőmegtartó műtét és szövetközi sugárkezelés az emlődaganat lokális kiújulásának kezelésére. Ötéves eredmények

et al. 2018

Self Cite

View full text Add to dashboard Cite

Second breast conserving therapy with perioperative high-dose-rate interstitial brachytherapy is a safe and feasible option for the management of ipsilateral breast tumor recurrences. Interstitial brachytherapy may decrease the risk of second local relapse with acceptable cosmetic results and low rate of late side effects. Hence, in selected cases it can provide a feasible alternative to salvage mastectomy. Orv Hetil. 2018; 159(11): 430-438.

show abstract

“…[20][21][22][23][24][25][26][27][28][29][30][31][32] Three articles were results of the German-Austrian accelerated partial breast irradiation (APBI) Phase II study. 22,25,26 Because the most recent data published by Ott et al did not include data on toxicity, we included the other two articles in our analysis.…”

Section: 12mentioning

confidence: 99%

“…The toxicity figures of the GermanAustrian APBI study were lower, but follow-up time was short. 25,26 In recurrent breast cancer, most studies 20,21,24,29,30,32 treated only locally with interstitial tubes or a chest wall mould. Resch et al 32 and four patients in the study of Niehoff et al 24 combined brachytherapy with EBRT.…”

Section: 12mentioning

confidence: 99%

A review of the clinical experience in pulsed dose rate brachytherapy

Balgobind

Koedooder

Zúñiga

et al. 2015

BJR

View full text Add to dashboard Cite

Pulsed dose rate (PDR) brachytherapy is a treatment modality that combines physical advantages of high dose rate (HDR) brachytherapy with the radiobiological advantages of low dose rate brachytherapy. The aim of this review was to describe the effective clinical use of PDR brachytherapy worldwide in different tumour locations. We found 66 articles reporting on clinical PDR brachytherapy including the treatment procedure and outcome. Moreover, PDR brachytherapy has been applied in almost all tumour sites for which brachytherapy is indicated and with good local control and low toxicity. The main advantage of PDR is, because of the small pulse sizes used, the ability to spare normal tissue. In certain cases, HDR resembles PDR brachytherapy by the use of multifractionated low-fraction dose.

show abstract

Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: Multicentric study of the GEC-ESTRO Breast Cancer Working Group

Cited by 136 publications

References 29 publications

Proton Therapy for Breast Cancer: Progress & Pitfalls

Proton Therapy for Breast Cancer: Progress & Pitfalls

Második emlőmegtartó műtét és szövetközi sugárkezelés az emlődaganat lokális kiújulásának kezelésére. Ötéves eredmények

A review of the clinical experience in pulsed dose rate brachytherapy

Contact Info

Product

Resources

About